Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.medcli.2020.12.036 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Additional benefits of belimumab in chronic phase of systemic lupus erythematosus and efficacy of tacrolimus combination therapy.
Immunol Med
December 2024
Department of Internal Medicine and Rheumatology, Juntendo University Urayasu Hospital, Urayasu, Japan.
Systemic lupus erythematosus (SLE) is a typical autoimmune disease; although severe disease and refractoriness to existing therapies are still experienced, the number of cases resistant to remission induction has decreased with the establishment of various therapies. However, improving long-term prognosis remains a challenge due to the unavoidable prolonged use of non-selective glucocorticoids. To investigate the additional effect of belimumab in the chronic phase, we included 28 of 46 patients with SLE who were initiated on belimumab between January 2018 and October 2022 for glucocorticoid reduction.
View Article and Find Full Text PDFLupus nephritis randomised controlled trials: evidence gaps and under-represented groups.
Lupus Sci Med
December 2024
Department of Nephrology and Mineral Metabolism, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Objective: We performed a scoping review of randomised clinical trials (RCTs) assessing pharmacological therapies for the initial management of lupus nephritis (LN), focusing on study design, included populations and outcome definitions, to assess the generalisability of their results and identify gaps in the evidence.
Methods: RCTs evaluating pharmacological interventions for the initial therapy of LN published between 2000 and 2024 were evaluated. Extracted variables included study design, selection criteria, outcome definitions, populations recruited and clinical characteristics of participants.
Autoimmune hepatitis: Towards a personalized treatment.
World J Hepatol
November 2024
Department of Pediatrics, CHU Sainte-Justine, Montreal H3T 1C5, Quebec, Canada.
Autoimmune hepatitis is an uncommon condition that affects both adults and children and is characterized by chronic and recurrent inflammatory activity in the liver. This inflammation is accompanied by elevated IgG and autoantibody levels. Historically, treatment consists of steroids with the addition of azathioprine, which results in remission in approximately 80% of patients.
View Article and Find Full Text PDFTofacitinib for child-onset systemic lupus erythematosus.
Front Immunol
October 2024
Department of Pediatrics, Shengjing Hospital of China Medical University, Shenyang, China.
Background: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that can cause diverse clinical manifestations in multiple organ systems. Child-onset SLE (cSLE) is associated with significantly higher morbidity and mortality than adult-onset SLE. The traditional treatments for SLE (glucocorticoids, antimalarials, conventional and biological disease-modifying antirheumatic drugs) often have significant adverse effects and may not fully control disease activity.
View Article and Find Full Text PDFSerum IFN-γ Predicts the Therapeutic Effect of Belimumab in Refractory Lupus Nephritis Patients.
Pharmgenomics Pers Med
September 2024
Department of Rheumatology and Immunology, The Affiliated Huaian No. 1 People's Hospital of Nanjing Medical University, Huaian, 223001, People's Republic of China.
Article Synopsis
- The study aimed to assess the effectiveness of belimumab in patients with refractory lupus nephritis (LN) and to identify serum biomarkers that could predict treatment responses.
- Fourteen patients with different subtypes of refractory LN were evaluated, and after six months of treatment with belimumab, most showed improvement in their disease activity and a reduction in medication dosage.
- Notably, high baseline levels of the serum cytokine IFN-γ were linked to poorer treatment outcomes, suggesting that these levels could help in tailoring future treatment strategies for patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!